Sarepta Therapeutics announced on Monday that Michael Severino, previously the chief executive of Tessera Therapeutics, will become the company’s new chief executive. The company said Severino will take the role starting the Tuesday after the announcement. He replaces Doug Ingram, who had disclosed earlier in 2026 that he would retire after nearly a decade at the helm of the biotech.
Sarepta’s executive transition follows a difficult stretch for the Cambridge, Massachusetts–based biotech. During Doug Ingram’s tenure, the company obtained approval for three therapies intended to treat Duchenne muscular dystrophy. However, those approvals did not end controversy: the company has faced persistent questions about the effectiveness of its Duchenne treatments.
Regulatory scrutiny has also shadowed Sarepta. The company’s gene therapy program drew attention from regulators after safety concerns emerged; previous reporting linked regulatory review to a patient death connected with the gene therapy. Those safety questions and broader doubts about clinical benefit have been part of the headwinds facing the company.
Investors have responded to these challenges. Sarepta’s share price has declined substantially from its level at the beginning of 2025, reflecting market unease about clinical, regulatory, and commercial prospects.
Doug Ingram led Sarepta for nearly ten years before announcing his intention to retire earlier in 2026. Under his leadership, the company secured three approvals for Duchenne-focused products. The source material does not provide the names of those products, the dates of approval, or detailed trial results; those specifics were not reported in the source.
While regulatory approvals represent important milestones for Sarepta, the company has continued to contend with scrutiny over clinical effectiveness and safety. The source reports that regulators examined safety issues tied to a gene therapy and that questions have persisted about how effective the approved therapies are for people with Duchenne muscular dystrophy.
Michael Severino comes to Sarepta from Tessera Therapeutics, where he served as chief executive. The source does not provide further details about Severino’s tenure at Tessera — such as the length of his service, achievements there, or the circumstances of his departure — nor does it include any commentary from Severino, Sarepta’s board, or other company executives.
The reporting notes that Sarepta has experienced a substantial drop in its share price relative to its position at the start of 2025. The source attributes the decline to the combination of questions over treatment effectiveness and regulatory scrutiny but does not provide specific share-price figures or the broader financial results for Sarepta.
Investors and industry observers will be watching whether the leadership change brings new strategic direction on clinical development, safety oversight, and commercial execution. The source does not specify any planned strategic shifts, reorganizations, or management initiatives tied to Severino’s appointment.
The STAT article provided the core facts of the leadership change but left several details unreported in the piece cited here. The source did not include:
The source confirms the leadership change and the context that led up to it — approvals for Duchenne therapies, questions about effectiveness, regulatory scrutiny over gene therapy safety, and a weakened share price. The piece does not outline next steps from Sarepta’s management or the board, nor does it provide a timeline for Severino’s early actions as CEO.
Stakeholders seeking fuller coverage and additional details will find the original reporting behind STAT’s STAT+ subscriber access. The source article indicates there is more to the story available to subscribers, but those additional contents were not included in the material provided here.
For readers seeking the full STAT article and any additional reporting the outlet published about this leadership change and Sarepta’s situation, the original item was published by STAT and included extended content available to STAT+ subscribers.
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.